Provexis signs commercial agreement

14:26 EDT 10 Oct 2017 | BioNow

Life-science company Provexis, which is developing medical food and dietary supplements, has taken another step towards the commercialisation of its flagship product Fruitflow. The company has signed a long-term alliance agreement with Swiss multinational DSM Nutritional Products, to give it the exclusive rights to develop, market and sell the product.  Fruitflow is a patented bioactive tomato extract that thins the blood. The agreement comes as Provexis revealed that it has narrowed full-year losses after what Chief Executive Stephen Moon described as a 'strong' year for the company. He also added that the business, which has research and development operations in Liverpool, is now looking for acquisition opportunities to increase its market share. 

Original Article: Provexis signs commercial agreement


More From BioPortfolio on "Provexis signs commercial agreement"

Quick Search


Relevant Topics

Food is any substance consumed to provide nutritional support for the body. It is usually of plant or animal origin, and contains essential nutrients, such as carbohydrates, fats, proteins, vitamins, or minerals. The substance is ingested by an organism ...

Alliances, mergers acquisitions and partnerships
BioPortfolio's alliances, mergers acquisitions and partnerships channel provides the latest news and corporate information on the global bio-pharmaceutical industry.

Collaborations in biotechnology
Commercial and academic collaborations are used throughout the biotechnology and pharmaceutical sector to enhance research and product development. Collaborations can take the form of research and evaluation agreements, licensing, partnerships etc. ...